Information Provided By: 
Fly News Breaks for January 27, 2017
ENDP
Jan 27, 2017 | 06:17 EDT
Piper Jaffray analyst David Amsellem lowered his price target for Endo International to $12 from $15 saying he does not believe the shares are positioned for a rebound. The analyst sees a "myriad" of near- and longer-term concerns, including the FDA panel meeting on Opana ER on March 13-14, continued pressure on the company's pain-focused assets and uncertainty over Vasostrict's exclusivity runway beyond a presumed 30-month stay expiring in 2019. Amsellem reiterates a Neutral rating on Endo.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
